VDRL Test: What Non-Reactive, Reactive and Equivocal Mean

At a Glance

VDRL stands for Venereal Disease Research Laboratory, the United States Public Health Service laboratory where the method was developed — it names a technique, not a disease. It is a screen for syphilis, and your result arrives as one word rather than a number. Reports print it as VDRL, V.D.R.L. or VDRL, Serum.

What it detects is the thing to understand first. VDRL does not look for Treponema pallidum, the bacterium that causes syphilis. It looks for reagin — antibodies that react with a mixture of cardiolipin, phosphatidylcholine and cholesterol. Those lipids sit in the bacterium's membranes and in your own cells alike; the CDC states the antibody rise during infection "is likely the result of a combination of antigens from both the bacteria and the host, not just from host tissue damage." Tests of this kind are nontreponemal. Because the target is not unique to the bacterium, reagin rises in syphilis and in conditions that have nothing to do with it. That is why a reactive result is followed by a second, different test, and why a non-reactive one is not the same as an all-clear.

Your report shows one of three stored values: Non-Reactive / Negative, Reactive / Positive, or Equivocal. Some laboratories also print weakly reactive, which is handled below.

How to read your result

Too early to show. Antibodies reacting in these tests can take up to two weeks to develop after a primary infection, per the CDC, and the sore marking that stage appears 10 to 90 days after exposure. A test inside that window can be non-reactive in someone infected.

The method's own limit. Against microscopy of a sore, VDRL sensitivity in primary syphilis has been reported between 50.0% and 78.4%, falling the longer an untreated infection runs: the CDC gives 63% to 66% in late latent and 47% to 64% in tertiary syphilis, where treponemal tests stay reactive.

If you remember only one thing

A reactive VDRL and a reactive treponemal test are not the same statement, and they behave in opposite ways. VDRL tracks activity and usually falls after treatment, sometimes as far as non-reactive — though some titers decline less than expected, and some stay reactive at a low level. Treponemal tests record that you met the bacterium, and the CDC states that the majority of people with a reactive one will have it for the rest of their lives. Anyone treated for syphilis watching two results move in opposite directions is watching them do exactly what they should.

Two people, same result

Two reports both read Non-Reactive / Negative.

The first was screened on a routine panel, no symptoms and no known exposure. Her VDRL found no reagin, and there is nothing further to read into it.

The second belongs to someone treated fourteen months ago, when his VDRL titer was 1:32. His report is the end of a line rather than a screen: what his clinician reads is the distance from 1:32 and the time it took. His treponemal test, run at diagnosis, is still reactive and will probably remain so — the CDC states that "the majority of patients who have reactive treponemal tests will have reactive tests for the remainder of their lives, regardless of adequate treatment or disease activity."

Same word, two meanings, because why a test was ordered is part of what it says.

Why VDRL and RPR results are not interchangeable

Both are nontreponemal tests detecting reagin, so they answer the same screening question. Their numbers do not transfer. The CDC is direct: titers from "RPR, VDRL, and other nontreponemal (lipoidal antigen) tests should not be used interchangeably to manage patients because they are different test methods." For following a result over time it asks that specimens be tested using the same nontreponemal method and specimen type.

In practice: a VDRL of 1:8 last year and an RPR of 1:32 this year is not a fourfold rise, because those two figures were never on the same scale. Two VDRL titers from different laboratories are a weaker comparison, not a void one: the CDC prefers one laboratory because titers vary between them. One difference does belong to VDRL alone — it is validated on spinal fluid, and RPR is not.

When VDRL is run on spinal fluid

CSF-VDRL is the only test the FDA has cleared to help diagnose neurosyphilis, and it is a separate test on a separate specimen. A reactive serum VDRL says nothing about whether an infection has reached the nervous system; the CDC states that examination of spinal fluid "is required to confirm CNS invasion." Published sensitivity figures differ sharply — roughly 30% to 86% across series — so a non-reactive CSF-VDRL does not rule neurosyphilis out, and blood in the sample undermines it. Syphilis can reach the nervous system, the eye or the ear at any stage.

What this result cannot tell you

Whether you have syphilis. Reagin is not specific to it; a treponemal test separates the two.

Whether an infection is current or was treated years ago. A reactive pair fits both; history decides.

When an infection was acquired. It reports what is detectable now.

Whether an infection is too recent to appear. Serology can be non-reactive early.

Whether treatment worked. That needs the titer before treatment, the titer now and the interval between — the word carries none of the three.

Whether syphilis involves the nervous system, the eyes or the ears. A serum result establishes none of the three, and they are not established the same way. Neurologic findings can lead to an examination of spinal fluid; ocular symptoms call for an eye examination, and the CDC does not require spinal fluid testing in every ocular case.

Common interpretation mistakes

Reading a reactive VDRL as a syphilis diagnosis. The treponemal test carries that.

Reading Equivocal as closer to negative than positive. It is neither — unresolved, and a reason to complete the testing.

Comparing a VDRL titer against an RPR titer. Different methods, so the two figures are not on a common scale. For two VDRL titers, the same laboratory is preferred rather than required, because results can vary between laboratories.

Expecting a treponemal test to turn negative after treatment. It ordinarily does not, and a reactive one years later is not evidence of failure.

Treating a non-reactive result as a window-period all-clear. Antibodies take time, and the method misses some primary infections.

Assuming a high titer rules out a false positive. It does not. In a surveillance series of 526,540 reactive nontreponemal results, 88.4% of false positives sat at 1:4 or below — but high-titer ones occurred too, and RPR was the method for 99.5% of them, so that spread describes RPR titers, not VDRL's.

Questions your doctor may ask

Have you had a reactive syphilis test before, and do you know its titer and date?

Have you been treated for syphilis, and when?

Is there a possible exposure, and how recently?

Any symptoms — a painless sore, a rash that can include the palms and soles, swollen glands, patchy hair loss?

Are you pregnant, and do you have HIV, an autoimmune condition or a recent vaccination?

Are there earlier results from the same test, and which laboratory ran them?

Read together with

Treponema pallidum Antibodies — confirms or contradicts a reactive VDRL.

RPR Titer — a related quantitative nontreponemal result, by a different method. The two titers are not substituted for one another over time; VDRL has its own serum titer.

HIV screening — run alongside, and itself a cause of false-positive reagin.

Hepatitis B and C serology — on the same profile.

Clinical pearls

A reactive nontreponemal test with a non-reactive treponemal test has a name. The CDC calls it a biological false positive, from malaria, leprosy, HIV, recent vaccinations, autoimmune disorders or injection drug use; a Florida and New York City series adds pregnancy, older age, cancers and hepatitis C. In that series 11% of reactive nontreponemal results were false positives, against a population prevalence the CDC puts at 0.2% to 0.8%.

The failure to be aware of is a false negative at very high antibody levels. When there is too much antibody for the reaction to form a lattice, the test reads non-reactive. This is the prozone, or hook, effect. In the RPR series the CDC reviewed, prozone appeared in under 0.85% of results overall but in 4.7% of primary and 1.8% of secondary syphilis — and laboratories do not routinely dilute non-reactive samples to look for it. A clinician who suspects syphilis despite a non-reactive undiluted result has to ask for a prozone rule-out.

Which test runs first is not settled practice. The traditional algorithm screens with a nontreponemal test and confirms with a treponemal one; the reverse sequence algorithm starts with a treponemal immunoassay. The CDC accepts both. In a 2015 College of American Pathologists survey its 2024 recommendations cite, 63.1% of responding laboratories reported using the traditional order — and the CDC adds that those surveys need updating, so this describes practice as last measured rather than practice today.

A titer that falls but never disappears is not the same finding as one that barely falls. The CDC calls the first the serofast state — the titer declines as expected but does not go away — and records it more in people treated over a year after infection or with repeat episodes. The second is an inadequate serologic response: in one trial of 541 patients treated for early syphilis, 14% had less than a fourfold decline at twelve months. That figure belongs to that population; expected response varies by stage. Both are read beside the pre-treatment titer and the stage.

Clinical Takeaway

VDRL is a nontreponemal, ordinal screen for syphilis, reporting reagin rather than the organism, with Non-Reactive / Negative as the value the marker is measured against. A reactive result calls for a treponemal confirmatory test and an endpoint titer, while an equivocal one follows the reporting laboratory's protocol — repeat testing, treponemal testing, or both; a non-reactive result does not exclude early infection, prozone interference, or long-standing untreated disease, where sensitivity falls to 47% to 64%. Nontreponemal titers track disease activity and usually fall after treatment, though some decline less than expected and some remain persistently reactive; treponemal reactivity persists in the majority of patients, so the nontreponemal titer is the serologic measure used to follow treatment response, read alongside the clinical course and the possibility of reinfection. Serial titers require the same nontreponemal method and specimen type; the same laboratory is preferred, because titers can vary between them. CSF-VDRL is a separate test on a separate specimen and is the only FDA-cleared assay for neurosyphilis.

In one sentence

A VDRL screen reports whether reagin antibodies are present today, so non-reactive is what it expects to find and reactive is the start of a confirming process rather than the end of one.

Bottom line

If your report reads Non-Reactive / Negative, that is the stored value this marker is compared against, and nothing runs from it automatically. What it does not close off is timing: a recent possible exposure, or symptoms that fit syphilis, are reasons to ask about testing again rather than to read the word as settled.

If it reads Reactive / Positive, the next step is a treponemal test — one that detects an antibody response to antigens specific to Treponema pallidum — plus a titer. If it reads Equivocal, what follows is whatever the reporting laboratory's protocol calls for: a repeat specimen, a treponemal test, or both. Reagin turns up in conditions unconnected to syphilis, and the treponemal test is what tells the two apart. If you are pregnant, either result is followed up promptly rather than left for the next appointment, because untreated syphilis can pass to the baby.

If you are being followed after treatment, watch the titer rather than the word. A fourfold change — two dilutions, such as 1:16 to 1:4 — is the CDC's threshold for a difference that means something, and it is read against a titer from the same test on the same kind of specimen. The same laboratory is preferred too, because titers can vary between laboratories.